| Project Number | pCODR 10109 |
|---|---|
| Brand Name | Keytruda |
| Generic Name | Pembrolizumab |
| Tumour Type | Lymphoma and Myeloma |
| Indication | classical Hodgkin Lymphoma (cHL) |
| Funding Request | For patients with classical Hodgkin Lymphoma (cHL) who failed to achieve a response or progressed after ASCT and have relapsed after treatment with or failed to respond to brentuximab vedotin post ASCT; or who did not receive an ASCT and have relapsed after treatment with or failed to respond to brentuximab vedotin; or who failed to respond to or progressed after ASCT and have not received brentuximab vedotin post ASCT |
| Review Status | Under Review |
| Pre Noc Submission | Yes |
| NOC Date | |
| Manufacturer | Merck Canada Inc. |
| Submitter | Merck Canada Inc. |
| Submission Date | July 7, 2017 |
| Submission Deemed Complete | July 14, 2017 |
| Submission Type | New Indication |
| Prioritization Requested | Requested and Granted |
| Stakeholder Input Deadline ‡ | July 21, 2017 |
| Check-point meeting | September 6, 2017 |
| pERC Meeting (target date) | |
| Initial Recommendation Issued (target date) | |
| Feedback Deadline (target date) ‡ | |
| pERC Reconsideration Meeting (target date) | |
| Final Recommendation Issued (target date) | |
| Notification to Implement Issued |
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.